Antitumoural activity of Brazilian red propolis fraction enriched with xanthochymol and formononetin: An in vitro and in vivo study

Autor(es)

Novak, Estela Maria ^{[1, 2, 3]} ; Costa Silva, Martha Silveira e ^[1] ; Marcucci, Maria Cristina ^[4] ; Helena Frankland Sawaya, Alexandra Christine ^[5] ; Lopez, Begona Gimenez-Cassina ^[5] ; Henriques Zanella Fortes, Maria Angela ^[6] ; Giorgi, Ricardo Rodrigues ^[6] ; Marumo, Kamila Tamie ^[7] ; Rodrigues, Rosangela Felipe ^[8] ; Maria, Durvanei Augusto ^[8]

Afiliação do(s) autor(es)

^[1] Fundacao Prosangue Hemoctr Sao Paulo, BR-05403000 Sao Paulo - Brazil

^[2] Lab Invest Med LIM 36 ICR HCFMUSP, Sao Paulo - Brazil

^[3] Inst Tratamento Canc ITACI ICR HCFMUSP, Sao Paulo - Brazil

^[4] Univ Bandeirante Anhanguera Sao Paulo, Grad Program Biotechnol & Pharm, Sao Paulo, SP - Brazil

^[5] State Univ Campinas UNICAMP, Biosci & Technol Bioact Prod Postgrad Program, Dept Plant Biol, Inst Biol, Campinas, SP - Brazil

^[6] Univ Sao Paulo, Fac Med, LIM 25, Cellular & Mol Endocrinol Lab, Sao Paulo, SP - Brazil

^[7] Butantan Inst, Biochem & Biophys Lab, Sao Paulo - Brazil

^[8] Univ Sao Paulo, Fac Vet Med & Anim Sci, Dept Surg, Sao Paulo, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Journal of Functional Foods; v. 11, p. 91-102, NOV 2014.
• Citações Web of Science: 15

Resumo

In this study, ultra-high performance liquid chromatography-mass spectrometry and tandem mass spectrometry of selected ions were used to characterise the ethanolic extract of a sample of Brazilian red propolis (EEBRP) and an active fraction (BRP-IV) containing xanthochymol and formononetin. The antiproliferative effect of BRP-IV was assayed using melanoma tumour xenografts in mice and HL-60, K562, RPMI8226, B16F10 cell lines. This fraction inhibited growth of tumour cell lines with IC50 values of 20.5 +/- 2.4 to 32.6 +/- 2.6 mu g/mL while EEBRP induced cytotoxic effect with IC50 values of 29.7 +/- 1.5 to 42.1 +/- 8.7 mu g/mL. BRP-IV also inhibited the proliferation of B16F10 cells by blocking cell cycle progression in the G2/M phase and inducing apoptosis. Administration of 10 mg/kg/day BRP-IV suppressed the growth of B16F0 tumour xenografts in C57BL/6 mice with less general toxicity than control groups. Taken together, these results indicate that BRP-IV can be considered a promising anticancer drug for the treatment of human cancers. (C) 2014 Elsevier Ltd. All rights reserved. (AU)

• Processo FAPESP: 12/03091-4 - Análise da composição de amostras de própolis vermelha do Brasil por espectrometria de massas com ionização por eletrospray e cromatografia líquida de ultra-eficiência (UPLC-ESI-MS) e avaliação da atividade antioxidante e antimicrobiana.
• Beneficiário: Begona Gimenez-Cassina Lopez
• Linha de fomento: Bolsas no Brasil - Mestrado